Virtu Financial LLC Invests $728,000 in argenx SE (NASDAQ:ARGX)

Virtu Financial LLC bought a new position in argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,184 shares of the company's stock, valued at approximately $728,000.

Several other hedge funds have also made changes to their positions in the company. Whipplewood Advisors LLC purchased a new stake in shares of argenx in the fourth quarter worth approximately $37,000. Global Retirement Partners LLC grew its stake in argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after purchasing an additional 48 shares in the last quarter. Jones Financial Companies Lllp increased its position in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after purchasing an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in shares of argenx by 78.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock valued at $46,000 after buying an additional 33 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after buying an additional 21 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. William Blair reissued an "outperform" rating on shares of argenx in a report on Friday, February 28th. Robert W. Baird boosted their price objective on shares of argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 4th. Citigroup reiterated an "outperform" rating on shares of argenx in a report on Friday, February 28th. Wells Fargo & Company upped their price target on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $687.00.

Remove Ads

argenx Stock Up 1.7 %

ARGX traded up $9.81 during trading on Thursday, hitting $593.47. The company had a trading volume of 362,492 shares, compared to its average volume of 283,948. The firm's 50-day moving average price is $629.28 and its 200 day moving average price is $600.95. The company has a market capitalization of $36.06 billion, a PE ratio of -674.40 and a beta of 0.59. argenx SE has a one year low of $352.77 and a one year high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. Sell-side analysts forecast that argenx SE will post 3.13 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.